PLX-R18 paracrine hematopoietic regeneration
PrimaryPLX-R18 is proposed to improve hematopoietic recovery by acting as an intramuscular depot of ex vivo expanded placenta-derived stromal cells that secrete cytokines and hematopoietic factors. These secreted factors are claimed to support recovery of hematopoietic progenitor cells, regeneration of multiple blood lineages, maturation and differentiation of hematopoietic cells, and migration of cells into peripheral blood. Testable predictions are that PLX-R18 treatment should increase peripheral blood counts over time, reduce transfusion dependence, and protect or rescue animals or patients from hematopoietic failure after radiation injury or incomplete recovery after hematopoietic cell transplantation.
Popperian evaluation
The core premise is credible: PLX-R18 is an intramuscular placenta-derived stromal cell product, and the cited evidence says these cells can act as a local depot that secretes cytokines and hematopoietic factors. That is a coherent mechanism for influencing recovery after marrow injury. The weaker link is distribution: we do not fully understand whether factors secreted in muscle reach bone marrow and systemic hematopoietic compartments at levels high enough to drive the whole effect.
Supporting evidence: PLX-R18 is described as an ex vivo expanded human placenta-derived stromal cell product administered intramuscularly.; Evidence nodes report that PLX-R18 can persist functionally as a local depot and secrete cytokines and hematopoietic factors.; Secreted factors are linked to progenitor recovery, maturation, differentiation, and migration.
Counter evidence: The paracrine interpretation is marked as a medium-confidence assumption rather than a settled fact.; The theory requires biologically meaningful signaling from intramuscular tissue to marrow and blood compartments, which remains a medium-confidence assumption.
The theory explains the observed pattern reasonably well: multilineage blood-count recovery, lower transfusion use, and radiation rescue all fit a hematopoietic support mechanism. The catch is attribution. In the post-HCT setting, peripheral counts can improve because of natural recovery, transfusions, patient selection, or transient redistribution. The evidence supports the theory, but it does not yet force the paracrine mechanism as the best explanation.
Supporting evidence: A phase I post-HCT study reported increases in hemoglobin, lymphocytes, neutrophils, and platelets over months after two PLX-R18 administrations.; Platelet transfusions fell from 5.09 units per month at baseline to 0.55 units per month at month 12.; Red blood cell transfusions fell from 2.91 units per month at baseline to 0 at month 12.; Preclinical studies report protection or mitigation of hematopoietic acute radiation syndrome in animal models.
Counter evidence: Improved peripheral counts may reflect unrelated recovery over time, transfusion effects, or redistribution rather than true hematopoietic regeneration.; The evidence context does not show direct in vivo coupling between measured PLX-R18-secreted factors, progenitor recovery, and later blood-count changes.
This theory is strongly testable. It predicts measurable changes in peripheral blood counts, transfusion requirements, survival after radiation injury, progenitor recovery, and lineage-specific regeneration. A controlled study showing no durable multilineage recovery, no transfusion reduction, or no rescue from hematopoietic failure would hit the theory directly. The cleanest falsifier would measure the secreted factors after intramuscular dosing and show that they do not track with marrow or blood recovery.
Supporting evidence: The theory predicts increased peripheral blood counts over time across multiple lineages.; It predicts reduced platelet and red blood cell transfusion dependence.; It predicts protection or rescue from hematopoietic failure and lethality after radiation injury.; It predicts improvement after incomplete hematopoietic recovery following hematopoietic cell transplantation.
Counter evidence: Some clinical endpoints, especially post-HCT recovery, need controls because spontaneous improvement can mimic treatment effect.; The paracrine mechanism needs direct factor measurements, not only downstream blood counts.
Reasoning tree
Public endorsements
Arthur Machlenkin is publicly identified as Pluri's Chief Scientific Officer, but the reviewed evidence does not show him publicly discussing PLX-R18's proposed paracrine mechanism, hematopoietic recovery claims, or any contradiction of them. On this theory, he is publicly silent in the supplied record.
The provided evidence does not show any public statement from Liat Zalts about PLX-R18 or its proposed paracrine hematopoietic mechanism. The only record is a generic company executive page with a broad company description, not a theory-specific comment from her.
The evidence identifies Lior Raviv as Pluri's CTO and separates him from unrelated namesakes, but it does not show any public statement from him about PLX-R18, paracrine hematopoietic regeneration, cytokine secretion, hematopoietic recovery, or related trial claims. The one quoted statement concerns plant-cell biomanufacturing for cacao and coffee, which is unrelated. On this record, he stays silent on the theory.
Michal Sheleg is a listed Pluri-Biotech co-author on the 2023 phase I PLX-R18 paper and the 2025 correction, both of which publicly state the proposed paracrine mechanism and report increased blood counts plus reduced transfusion need after intramuscular PLX-R18. She is also a co-author on the 2022 mouse study reporting that intramuscular PLX-R18 increased survival, bone marrow progenitors, and peripheral blood cellularity after radiation injury. Co-authorship on these papers is public endorsement of the theory, not silence.
Evidence publication IDs: f479cdc3-46d8-49fd-b76b-e138028d324a, 69500624-198c-427a-8a03-affe032199a4, 55b182c7-989d-4fde-9dee-7e2e923fe972